Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 8—August 2023
Dispatch

Mycobacterium abscessus Meningitis Associated with Stem Cell Treatment During Medical Tourism

Andrew B. Wolf, Kelli M. Money, Arun Chandnani, Charles L. Daley, David E. Griffith, Lakshmi Chauhan, Nathan Coffman, Amanda L. Piquet, Kenneth L. Tyler, Shanta M. Zimmer, Brian T. Montague, Sarah Mann, and Daniel M. PastulaComments to Author 
Author affiliations: University of Colorado School of Medicine, Aurora, Colorado, USA (A.B. Wolf, K.M. Money, A. Chandani, L. Chauhan, N. Coffman, A.L. Piquet, K.L. Tyler, S.M. Zimmer, B.T. Montague, S. Mann, D.M. Pastula); National Jewish Health, Denver, Colorado, USA (C.L. Daley, D.E. Griffith); Colorado School of Public Health, Aurora (D.M. Pastula)

Main Article

Table 2

Final treatment regimen for Mycobacterium abscessus meningitis for case patient who underwent intrathecal stem cell injections as treatment for multiple sclerosis at a clinic in Mexico

Drug
 Dose
Azithromycin 500 mg IV 1×/d
Ceftaroline 600 mg IV 3×/d
Eravacycline 80 mg IV 1×/d
Imipenem 500 mg IV 4×/d
Tedizolid 200 mg orally 1×/d

*IV, intravenously.

Main Article

Page created: June 14, 2023
Page updated: July 20, 2023
Page reviewed: July 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external